Implications of the tumor immune microenvironment for staging and therapeutics
Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL, Cimino-Mathews A. Implications of the tumor immune microenvironment for staging and therapeutics. Modern Pathology 2017, 31: 214-234. PMID: 29192647, PMCID: PMC6132263, DOI: 10.1038/modpathol.2017.156.Peer-Reviewed Original ResearchConceptsTumor immune microenvironmentImmune microenvironmentTumor typesTumor microenvironmentAnti-PD-1/PD-L1Therapeutic targetPD-1/PD-L1 axisFirst line treatment algorithmHost antitumor immune responseEarly stage colorectal carcinomaLocal immune contextureImmune checkpoint inhibitorsPD-L1 axisAntitumor immune responseImmune-based therapiesPD-L1 antibodiesAbundance of CD8Th1 helper cellsNovel therapeutic targetPotential therapeutic targetPrimary organ siteNew candidate biomarkersNumerous tumor typesSpecific tumor typesCurrent TNM